Symbiomix Therapeutics
Biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections than can have serious health consequences.
Launch date
Employees
Market cap
-
Enterprise valuation
€136m (Public information from Oct 2017)
Newark New Jersey (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
$41.0m | Series A | ||
N/A | $6.0m | Early VC | |
$150m Valuation: $150m | Acquisition | ||
N/A | Early VC | ||
Total Funding | €42.7m |
Related Content
Recent News about Symbiomix Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.